Drug intelligence / Profile preview

Bifidobacterium breve PRL2020

Development stage: Preclinical
Lead developer: Pharmextracta
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium breve PRL2020 is a specific probiotic strain, marketed as Brevicillin®, being investigated for its ability to mitigate the gastrointestinal side effects of antibiotic therapy. A key feature of this strain is its intrinsic and non-transferable resistance to amoxicillin and amoxicillin/clavulanate, which allows it to survive in the gut during treatment with these common antibiotics. [1, 9] By maintaining the population of beneficial bifidobacteria, it helps to preserve the balance of the gut microbiota, which can reduce the incidence of antibiotic-associated diarrhea (AAD) and abdominal pain in patients, including children. [6, 10] The product is developed by Pharmextracta and has been the subject of clinical studies, including one sponsored by Liaquat University of Medical and Health Sciences. [6]

Brand names: Brevicillin

Beyond the preview

Go deeper on Bifidobacterium breve PRL2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium breve PRL2020.

Explore the full profile